Full Event Guide

Screenshot 2022-10-21 163146

Agenda Highlights Include:

  • Tackle complex heterogenous diseases with multiple antigens by targeting the primary drivers of disease with Parvus Therapeutics and Sonoma Biotherapeutics
  • Delve into the opportunities to develop tolerization therapies through autoimmune antigen-specific immune tolerance platforms with Selecta Bio and FDA CBER
  • Optimize novel technologies for effective delivery and evaluate nanoparticle, RNA, peptide, and other delivery approaches with insights from Toleranzia, Integrated Nanotherapeutics and Allero Therapeutics